Navigation Links
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Date:5/6/2008

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using Catalyst's proprietary therapeutic protease platform technologies and know-how.

CB 813 is designed to substantially enhance clot-generating activity at the site of bleeding and therefore achieve clinical efficacy with fewer and lower doses than current therapy. In established hemophilia models of acute bleeding, CB 813 has demonstrated a significant improvement in potency compared with the marketed recombinant factor VIIa product, NovoSeven(R) and a competing, second-generation product, NN1731. Catalyst intends to file an Investigational New Drug (IND) application for CB 813 and commence human clinical studies in hemophilia patients in 2009.

"Patients receiving factor VIIa therapy typically require multiple doses of drug and extended treatment times to manage acute bleeding episodes," said Gilbert C. White, II, M.D., Executive Vice President for Research and Director, Blood Research Institute, Blood Center of Wisconsin. "I am excited by the potential shown by CB 813 to improve the efficiency of treatment by achieving a faster onset and an extended duration of therapeutic benefit to patients. These advantages may significantly reduce both the number of doses and treatment time required to manage bleeding and restore normal hemostasis."

"The selection of this development candidate is an exciting milestone for Catalyst. Created to more rapidly and effectively stop bleeding, CB 813 holds great promise as a new agent in the treatment of hemophilia," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "CB 813 is representat
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
2. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
3. Neurocrine Biosciences Reports First Quarter 2008 Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...S, France, July 24 /- NicOx...p-line results from the 52-week,open label safety ...ion of,the 301 phase 3 study for naproxcinod. The ... efficacy was maintained for the one-year duration... assessment scale. In,addition, the results showed...
(Date:7/23/2008)...3 /- Sound Pharmaceuticals (SPI) has ... the FDA for the clinical,testing of a proprietary...otherapy induced hearing loss or ototoxicity. The ... tested in advanced stage lung cancer,and head and...motherapy.,This marks the second development progr...
(Date:7/23/2008)...s Some Areas of the Body Have Greater Concentratio...3 /PRNewswire-USNewswire/ -- Fat removed,from the ...was found to be,an excellent source of stem cells,...reas of the body, reports a Brazilian-based study ... the official medical journal of the,American Soci...
(Date:7/23/2008)... on IND-Enabling Work with Protein Therapeutics th...ement System, CAMBRIDGE, Mass., July 23 /PRNewswi...t has initiated a corporate growth plan with the,a...utive officer and the,establishment of its headqua...odruff Emlen, M.D., a co-founder of the company wh...
Breaking Medicine Technology:NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Endocare Stock to Commence Trading on NASDAQ 3184 1Endocare Stock to Commence Trading on NASDAQ 3184 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 1Ingenuity Systems Launches New Metabolomics Solution Within IPA 1137 2Marriage 26 Family 3A Celebrating Holiday Traditions 3178 1Marriage 26 Family 3A Celebrating Holiday Traditions 3178 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 1QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 2QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 3QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 4QLT acquires leading edge ocular drug delivery system from ForSight Labs 3176 5
(Date:7/25/2008)...ncial results -, LAVAL, QC, July 25 /PRNewswire-F...) today announced that it will host a conference c...ss its second quarter 2008,financial results. Labo...l,results via news release at approximately 7:00 a...by telephone, dial 416-646-3095 or,1-800-814-4859....
(Date:7/25/2008)...stCall/ -- Thoratec,Corporation (Nasdaq: THOR ) a...ry support therapies to save, support and restore ...t its operating results for the second,quarter and... 31., The company will hold a conference call to ...ties to all interested parties at 1:30 p.m.,Pacif...
(Date:7/25/2008)...unction, increases asthma risk, studies find, ,... clean, fresh-smelling home may actually be bad fo...and air freshening products you use. , Recent r...s or air fresheners that contain a certain volatil...ne (1,4 DCB), can reduce lung function by 4 percen...
(Date:7/25/2008)... Society for Gastrointestinal Endoscopy (ASGE) has... bariatric surgery patient. The rising prevalence ... surgical interventions led to a marked increase i... the U.S., from 13,365 in 1998 to 102,794 in 2003....ive patient and the postoperative patient, and app...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3
...o epidemiologists has provided new information on ... bacteria in Post menopausal women and the associ...s showed that women infected with four bacteria kn...ore likely to have more severe oral bone loss than...
... ruled that Ontario residents can get cold and all...l grocery and corner stores . The Ontario Superio...harmaceutical regulators and the Ontario College o...elling medications containing ephedrine and pseudo...
...x Planck Institute for Brain Research in Frankfurt...icago have discovered that nocturnal fruit bats (...he retinas of most mammals contain two types of ph...ht vision and colour vision, and the more sensitiv...
...rogramme has been heavily promoted by the UK gover...alth care and deliver long term cost savings . But...e and question whether expert patients consume few...hief medical officer, Sir Liam Donaldson, conclude...
Other Medicine News:Health News:Post Menopausal Women are Prone to Gum Disease 2Health News:Canadian Court Rules Grocery Shops can Sell Cold Medications Containing Pseudoephedrine 2Health News:Research on Fruit Bats 2Health News:Research on Fruit Bats 3
... IOL power calculation software. All A-scans and A...e module with SRK II, SRKT, Holladay Dioptimum and...H 5100e are equipped with corneal compression dete...eadings. The only A-Scan in the world with corneal...
The AccuSonic A-scan makes it easy to obtain extreme accuracy and improved patient outcomes. Obtain accurate measurements with industry leading signal acquisition and processing.
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p
Medicine Products: